- Home
- BDRX vs SLRX Comparison
BDRX vs SLRX Comparison
Compare BDRX & SLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BDRX | SLRX |
|---|---|---|
| Founded | 2000 | N/A |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0M | 3.6M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | BDRX | SLRX |
|---|---|---|
| Price | $2.58 | $0.65 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 2.6M | 320.7K |
| Earning Date | 09-12-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.83 | $0.62 |
| 52 Week High | $92.00 | $108.00 |
Technical Indicators
Market Signals| Indicator | BDRX | SLRX |
|---|---|---|
| Relative Strength Index (RSI) | 38.98 | 26.30 |
| Support Level | $4.55 | $0.62 |
| Resistance Level | $7.22 | $0.72 |
| Average True Range (ATR) | 1.49 | 0.06 |
| MACD | -0.28 | 0.07 |
| Stochastic Oscillator | 1.21 | 14.08 |
Price Performance
Historical ComparisonAbout BDRX Biodexa Pharmaceuticals plc
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.
About SLRX Salarius Pharmaceuticals Inc.
Salarius Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical needs. The company has focused on two classes of drugs that address gene dysregulation: targeted protein inhibitors and targeted protein degradation. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader.